EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Prognostic Value of Dynamic Lactate Dehydrogenase Trends in Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma: Retrospective Cohort Study

Baidong Zhang iD, Zhichao Kang iD, Yi Ding iD, Wang Jing iD, Alei Feng iD, Renya Zeng iD, Jianan Li iD, Yi Zhao iD, Yuanliu Nie iD, Wentao Zhang iD, Lu Sun iD, Zhe Yang iD

JMIR Cancer · 2026

DOI: 10.2196/73576 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift JMIR Cancer, 2026. Verfasst von Baidong Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250000, Chin…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, L-Lactate Dehydrogenase, Esophageal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have emerged as a pivotal treatment for advanced esophageal squamous cell carcinoma (ESCC). However, their efficacy can significantly differ among patients, highlighting the need for reliable prognostic markers to enhance treatment outcomes. Lactate dehydrogenase (LDH) plays a key regulatory role in the complex relationship between cancer metabolism and the immune system, suggesting that monitoring LDH levels may provide valuable insights into treatment efficacy and inform personalized therapeutic strategies for advanced ESCC.

Objective

This study aimed to explore the prognostic significance of dynamic changes in LDH levels during ICI therapy in predicting treatment outcomes.

Methods

We retrospectively analyzed the clinical data of 126 patients with advanced ESCC who received first-line ICI therapy at the Department of Radiation Oncology, Cancer Center, Shandong Provincial Hospital, between April 2018 and November 2022. Serum LDH levels were measured after every 3 cycles of combined immunotherapy and chemotherapy. Receiver operating characteristic curve analysis determined the optimal LDH reduction threshold. Kaplan-Meier survival curves and Cox regression models assessed progression-free survival (PFS) and overall survival.

Results

Among the 126 patients, 55 (43.6%) were classified into the LDH-increased group, while 71 (56.4%) belonged to the LDH-decreased group. Within the LDH-increased group, 78.2% (43/55) of the patients were male, compared to 90.1% (64/71) in the LDH-decreased group. The median age of patients in the LDH-increased group was 59 (range 55‐68) years, whereas the median age in the LDH-decreased group was 65 (range 58‐65) years. LDH decrease following first-line ICI therapy was associated with improved outcomes compared to LDH increases (median PFS 13.4, IQR 8.1‐24.3 mo vs median 10.8, IQR 4.8‐20.6 mo; P = .03). Patients with a posttreatment LDH decrease of more than 14.4% had a median PFS of 11.1 (IQR 7.2‐24.3) months, whereas those with an LDH decrease between 0% and 14.4% had a median PFS of 21.7 (IQR 9.4‐34.5) months. Conversely, an increase in LDH resulted in a median PFS of 10.8 (IQR 4.8‐20.6) months. Patients with tumor reduction exhibited a significantly greater decrease in LDH levels compared with those without tumor reduction ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaL-Lactate DehydrogenaseEsophageal NeoplasmsImmunotherapyImmune Checkpoint InhibitorsBiomarkers, TumorHumansRetrospective StudiesMalePrognosisFemaleMiddle AgedAgedProgression-Free Survival

Stichwörter der Autor:innen

biomarkeresophageal squamous cell carcinomaimmune checkpoint inhibitorslactate dehydrogenaseprognostic value

Substanzen

L-Lactate DehydrogenaseImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250000, China, 86 0531-87938911.
  • Department of Radiation Oncology, Shandong Provincial Hospital, Jinan, China.

ORCID-Profile: Baidong Zhang, Zhichao Kang, Yi Ding, Wang Jing, Alei Feng, Renya Zeng, Jianan Li, Yi Zhao, Yuanliu Nie, Wentao Zhang, Lu Sun, Zhe Yang

Zitieren

APA

Zhang, B., Kang, Z., Ding, Y., Jing, W., Feng, A., Zeng, R., Li, J., Zhao, Y., Nie, Y., Zhang, W., Sun, L., & Yang, Z. (2026). Prognostic Value of Dynamic Lactate Dehydrogenase Trends in Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma: Retrospective Cohort Study. JMIR Cancer. https://doi.org/10.2196/73576

Vancouver

Zhang B, Kang Z, Ding Y, Jing W, Feng A, Zeng R, et al. Prognostic Value of Dynamic Lactate Dehydrogenase Trends in Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma: Retrospective Cohort Study. JMIR Cancer. 2026. doi:10.2196/73576

BibTeX
@article{Zhang2026,
  author = {Zhang, Baidong and Kang, Zhichao and Ding, Yi and Jing, Wang and Feng, Alei and Zeng, Renya and Li, Jianan and Zhao, Yi and Nie, Yuanliu and Zhang, Wentao and Sun, Lu and Yang, Zhe},
  title = {Prognostic Value of Dynamic Lactate Dehydrogenase Trends in Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma: Retrospective Cohort Study},
  journal = {JMIR Cancer},
  year = {2026},
  doi = {10.2196/73576}
}
Kostenlos starten →